Abstract
Bronchioloalveolar carcinoma (BAC) is considered a subtype of adenocarcinoma of the lung. Recently BAC has been variously termed adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant invasive adenocarcinoma, and invasive mucinous adenocarcinoma. The aim of the study was to analyze and detect prognostic factors of patients with BAC over a 7-year period. This retrospective single-center study included 44 patients with BAC. The impact on survival of fifteen variables (gender, age, smoking status, cough, dyspnea, hemoptysis, fever, chest pain, sputum, metastasis number, Karnofsky performance status, pT, pN, TNM stage, cytotoxic chemoterapy) were assessed. Median age was 55 years (38-83). Most patients were male (63.6%) and stage IV (59.1%). Twenty-one patients (47.7%) received cytotoxic chemotherapy (platinum-based regimens) for metastatic disease. Objective response rate was 33.3% (4 partial, 3 complete responses). Stable disease was observed in nine in patients (42.8%). Disease progression was noted in 5 (23.8%). The median OS for all patients was 12 months (95%CI, 2.08-22.9 months). Independent predictors for overall survival were: Karnofsky performance status (HR:3.30, p 0.009), pN (HR:3.81, p 0.018), TNM stage (HR:6.49, p 0.012) and hemoptysis (HR:2.31, p 0.046). Karnofsky performance status, pN, TNM stage and hemoptysis appear to have significant impact on predicting patient survival in cases of BAC.
Highlights
Lung cancer is the most common cancer worldwide (Jemal et al, 2011)
Neoadjuvant therapy was received in 1 patients (0.2%); adjuvant chemotherapy and/or radiation therapy was administered in 8 patients (18.1%)
In this study we have retrospectively reviewed the clinical characteristics of the patients diagnosed with Bronchioloalveolar carcinoma (BAC) according to the 2004 World Health Organization (WHO) classification
Summary
Lung cancer is the most common cancer worldwide (Jemal et al, 2011). Bronchioloalveolar carcinoma (BAC) accounts for approximately 3-4% of all lung cancers (Read et al, 2004). Advanced stage is most common.The treatment for patients with advanced BAC are limited (Kris et al, 2006). Prospective studies of paclitaxel as therapy for advanced BAC documented modest survival (Scagliotti et al, 2005; West et al, 2005). In patients with advanced BAC not selected on the basis of EGFR mutation was no statistically significant difference between erlotinib and chemotherapy (carboplatin plus paclitaxel) treatment for overall survival (Cadranel et al, 2011). Independent predictors for overall survival were: Karnofsky performance status (HR:3.30, p 0.009), pN (HR:3.81, p 0.018), TNM stage (HR:6.49, p 0.012) and hemoptysis (HR:2.31, p 0.046). Conclusions: Karnofsky performance status, pN, TNM stage and hemoptysis appear to have significant impact on predicting patient survival in cases of BAC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
